Beclometasone dipropionate given by either nebulizer suspension or metered-dose inhaler, provides comparable results among adult asthma patients, French researchers say. Forty patients (aged 27 and 60 years) who had intermittent bronchial asthma were enrolled into a double-blind, randomised, placebo-controlled trial at Hopital Arnaud de Villeneuve, Montpellier.
The patients were divided into 4 groups of 10 members each. They received, over three weeks, either: 1,600 micrograms day(-1) beclometasone dipropionate (BDP) suspension BID via a nebulizer; 3,200 micrograms day(-1) BDP suspension BID via a nebulizer; BDP 800 micrograms day(-1) BID via a metered-dose inhaler (MDI) plus spacer; or placebo.
At the end of the study, treatment responses by the patients were comparable for the primary pharmacodynamic endpoint of FEV1 in response to methacholine bronchial provocation testing. However, there was a statistically significant improvement among patients who received the BDP 3,200 micrograms day(-1) suspension for nebulisation group, compared with pre-treatment for other parameters, including FEV1 and peak expiratory flow rates.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!